GLP-1 Drugs Like Semaglutide Quietly Deplete Key Nutrients Over Time
A review of 480,000+ adults finds GLP-1 receptor agonist users face rising deficits in vitamin D, iron, calcium, and B vitamins.
Summary
A narrative review analyzing over 480,000 adults found that GLP-1 receptor agonists — including semaglutide, liraglutide, and tirzepatide — are linked to meaningful nutritional deficiencies. Vitamin D deficiency affected 13.6% of users by 12 months, iron levels ran 26–30% lower than comparator groups, and over 60% of users consumed below recommended levels for calcium and iron. Vitamin D intake averaged just 20% of recommendations. Thiamine and cobalamin deficits also worsened over time. The appetite suppression, delayed gastric emptying, and altered absorption caused by these drugs appear to drive these gaps, with downstream risks including lean muscle loss. Authors recommend targeted nutritional screening for at-risk patients.
Detailed Summary
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and tirzepatide have rapidly become among the most prescribed drugs globally for obesity and type 2 diabetes. Their effectiveness at reducing body weight is well established, but their broader nutritional consequences have received far less attention — until now.
This narrative review searched PubMed and the Cochrane Database for adult studies published between January 2019 and May 2025 that measured nutritional or micronutrient outcomes in GLP-1RA users. Six studies met inclusion criteria, collectively encompassing 480,825 adults — a dataset large enough to surface clinically meaningful patterns.
The findings reveal a consistent and worsening nutritional picture over time. Vitamin D deficiency was the most prevalent abnormality, rising from 7.5% at 6 months to 13.6% at 12 months. Iron depletion was also prominent: GLP-1RA users had ferritin levels 26–30% lower than those using SGLT2 inhibitors. More than 60% of users failed to meet estimated daily requirements for both calcium and iron, and average vitamin D intake was just one-fifth of recommended levels. Thiamine (B1) and cobalamin (B12) deficits also increased progressively. Insufficient protein and calcium intake contributed to lean mass loss — a concern for long-term metabolic and musculoskeletal health.
The likely mechanisms include appetite suppression reducing overall food intake, delayed gastric emptying altering nutrient absorption kinetics, and possible changes in gastrointestinal physiology affecting micronutrient bioavailability.
For clinicians and patients, the takeaway is clear: GLP-1RA therapy should not be managed in a nutritional vacuum. Individualized laboratory monitoring and dietary assessment appear warranted, particularly for those already at malnutrition risk. The authors caution that most data are observational, limiting causal conclusions.
Key Findings
- Vitamin D deficiency doubled from 7.5% at 6 months to 13.6% at 12 months in GLP-1RA users.
- GLP-1RA users had 26–30% lower ferritin levels compared to SGLT2 inhibitor users.
- Over 60% of GLP-1RA users consumed below recommended daily intakes of calcium and iron.
- Thiamine and cobalamin (B12) deficits worsened progressively over the treatment period.
- Protein and calcium insufficiency contributed to lean muscle mass loss over time.
Methodology
This is a narrative review following SANRA and PRISMA-ScR guidance, searching PubMed and the Cochrane Database from January 2019 to May 2025. Six studies met inclusion criteria, covering 480,825 adults; pediatric studies and those lacking nutrient endpoints were excluded. Data were synthesized descriptively rather than via meta-analysis.
Study Limitations
The review is based on only six studies, limiting statistical power and generalizability. All data are observational, preventing definitive causal attribution of deficiencies to GLP-1RA therapy versus underlying diet or disease. Heterogeneity in study populations, drug types, and follow-up duration may confound comparisons.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.